Previous Article | Next Article ![]()
Journal of Virology, October 2005, p. 12703-12713, Vol. 79, No. 20
0022-538X/05/$08.00+0 doi:10.1128/JVI.79.20.12703-12713.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama 35294-2170
Received 8 April 2005/ Accepted 18 July 2005
|
|
|---|
70% of NP396-specific memory cells are in the S phase of the cell cycle, as assessed by bromodeoxyuridine incorporation studies. Epitope-dependent differences during the proliferative phase of the secondary response were confirmed by adoptive transfer studies with CFSE-labeled T cells. Although NP396-specific T cells typically dominate secondary responses, the broader multiepitope-specific population of antiviral T cells is beneficial for controlling a variant virus with an escape mutation in this epitope. These findings indicate that the induction and maintenance of a focused response contribute to the clearance of secondary infections; however, a more diverse pool of antiviral T cells facilitates long-term immunity to mutable pathogens. |
|
|---|
Primary acute viral infections drive the development of long-lived pools of memory CD8 T cells (19, 32, 44, 50, 63). In this way, a beneficial memory of past antigenic experiences is established as an increased number of virus-specific T cells are maintained which are tuned to rapidly respond if they reencounter infected cells. Thus, if reexposure to the initial pathogen occurs, a preexisting population of antiviral T cells is available that can quickly elaborate effector functions which remove infected target cells before progeny virus is released. This ability to mount an accelerated recall response is a distinguishing trait of immunological memory (50, 63). Nevertheless, the overall population of memory T cells is heterogenous and comprised of phenotypically and functionally diverse subsets specific for a variety of viral epitopes (23, 64, 67). A key issue for infection control and vaccine development is delineating which components of this memory T-cell pool are most effective at clearing pathogens following secondary exposures.
Lymphocytic choriomeningitis virus (LCMV) infection of mice serves as an ideal system to probe the complexity of memory T-cell subsets. Acute infections of adult mice with this natural mouse pathogen elicit a massive virus-specific CD8 T-cell response (10, 13, 44, 62). This response is required for the resolution of the infection, and in H-2b mice the overall primary response is directed towards at least 10 epitopes (58, 59). As the primary response is downsized, populations of memory CD8 T cells emerge and are stably maintained over time (19, 32, 44). These memory cells confer resistance to intracranial rechallenge, which is lethal to naive mice, and also more rapidly control peripheral exposures to virulent viral isolates (10, 62). Thus, the LCMV system is a particularly suitable platform for examining the biological importance of memory CD8 T-cell subsets and how they participate in protective recall responses.
For the current study, we utilized the LCMV system to address how the ensemble of virus-specific memory CD8 T cells participates during the course of secondary viral exposures. Our findings show that reinfection of LCMV-immune mice induces a wave of activation of preexisting memory T cells which is detectable as early as 6 h after challenge. Although the secondary response is rapidly initiated, striking epitope-dependent differences are observed as "first responders" are preferentially recruited. This suggests that the differential maintenance and recruitment of epitope-specific T-cell subsets impact the capacity to optimally control secondary infections.
|
|
|---|
3 months after primary LCMV-Armstrong infection) were administered 2 x 106 PFU of LCMV clone 13 intravenously (i.v.). In certain experiments, naive mice were similarly inoculated to establish primary LCMV clone 13 infections. All viral isolates were originally provided by R. Ahmed (Emory University, Atlanta, GA) and were propagated in BHK-21 cells. The titers of viral stocks and tissue samples were determined by plaque assays using Vero cell monolayers (2). Cell preparation. Spleen and liver cells were prepared as described previously (36). Briefly, livers and spleens were harvested from mice following perfusion with 10 ml of phosphate-buffered saline (PBS). Spleens were disrupted into single-cell suspensions, and erythrocytes were removed by treatment with 0.83% (wt/vol) NH4Cl. Suspensions of liver cells were prepared, and liver lymphocytes were collected over a layer of Histopaque-1083 (Sigma-Aldrich, St. Louis, MO). After being washed, all cell preparations were resuspended in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS), 50 µM 2-mercaptoethanol, 100 U/ml penicillin, and 100 µg/ml streptomycin.
MHC class I tetramer preparation. MHC class I tetramers were prepared as previously described (20). Monomers were formed by refolding H-2Db or H-2Kb heavy chains with antigenic peptides and human ß2-microglobulin. Following purification, tetramers were formed by the stepwise addition of allophycocyanin-conjugated streptavidin (Molecular Probes, Eugene, OR).
MHC class I tetramer staining. Suspensions of spleen and liver cells were treated with anti-CD16/CD32 monoclonal antibody (clone 2.4G2) prior to staining with MHC class I tetramers and anti-CD8 antibody. For costaining with H-2Db tetramers, the anti-CD8-phycoerythrin (PE) antibody clone 53-6.7 (BD Pharmingen, San Diego, CA) was used; however, the anti-CD8-PE antibody clone CT-CD8a (Caltag, Burlingame, CA) was used in conjunction with H-2Kb tetramers. Fluorescein isothiocyanate (FITC)-conjugated antibodies were included to assess the expression of CD43 (1B11), CD44 (IM7), and CD62L (MEL-14). Cells were stained on ice in PBS, 2% (wt/vol) bovine serum albumin, and 0.2% (wt/vol) NaN3 (fluorescence-activated cell sorting [FACS] buffer) and subsequently washed three times in FACS buffer and fixed in PBS-2% (wt/vol) paraformaldehyde. Samples were acquired using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA), and data were analyzed using the computer program Cell Quest.
Ex vivo intracellular cytokine staining.
Intracellular cytokine staining was performed as previously described, but without additional peptide stimulation or brefeldin A treatment (14, 20). Briefly, freshly prepared suspensions of spleen and liver cells were costained with MHC class I tetramers and anti-CD8 antibodies as described above. Intracellular staining was performed using anti-gamma interferon (IFN-
)-FITC antibody (clone XMG1.2; BD Pharmingen, San Diego, CA) in accordance with previously described methodologies (20).
BrdU incorporation. The proliferation of antigen-specific CD8 T cells in vivo was monitored by measuring bromodeoxyuridine (BrdU; Sigma, St. Louis, MO) incorporation. For short labeling experiments, 0.8 mg BrdU in PBS was administered to mice by intraperitoneal injection 6 h before sacrifice. For long labeling experiments, BrdU (0.8 mg/ml) was given in daily changes of drinking water for a period of 6 days. To detect BrdU incorporation, freshly explanted splenocytes were stained with MHC class I tetramers and anti-CD8-PE antibodies. Stained samples were then fixed and permeabilized by overnight treatment at 4°C with 1% (wt/vol) paraformaldehyde and 0.05% Igepal (Sigma, St. Louis, MO) in PBS. The cells were then washed twice with PBS and incubated, with periodic mixing, for 30 min at 37°C in PBS containing 4.2 mM MgCl2 and 50-Kunitz units/ml DNase I, pH 5 (Sigma, St. Louis, MO). Cells were subsequently stained with a 1:20 dilution of anti-BrdU-FITC antibody (clone 3D4; BD Pharmingen San Diego, CA) prepared in PBS containing 5% FCS, 2% mouse serum, and 0.5% Igepal. After 45 min on ice, samples were washed twice and finally resuspended in PBS-1% (wt/vol) paraformaldehyde. Samples were analyzed by flow cytometry as described above.
CFSE labeling and adoptive transfers.
Splenocytes were prepared from immune Thy1.1 mice >3 months following primary infection with LCMV-Armstrong. CD8 T cells were enriched by positive selection with magnetic beads (Miltenyi, Auburn, CA) and then washed with PBS. Isolated cells were at least 87% CD8+. Cells (107 cells/ml) were then labeled with 4 µM 5 (and 6-)-carboxyfluorescein diacetate, succinimidyl ester (CFSE) (Molecular Probes, Eugene, OR) for 8 min at 25°C. Labeling was quenched by the addition of FCS, and cells were washed twice with PBS. CFSE-labeled CD8 T cells (
5 x 106) from LCMV-immune Thy1.1 mice were then transferred by i.v. injection into either naive or LCMV-immune B6 mice which had been primed with LCMV-Armstrong at least 3 months previously. The following day, recipient mice were either left untreated or infected with 2 x 106 PFU LCMV clone 13 i.v. On days 1, 2, and 4 following infection, recipient mice were sacrificed, and splenocytes were prepared as described above. Cells were costained with anti-Thy1.1-PE antibody (clone OX-7; BD Pharmingen) and MHC class I tetramers. Samples were analyzed by flow cytometry, and the diminution in green fluorescence was determined.
Isolation of LCMV variant F403L. Viral isolates were cloned from serum samples obtained from C57BL/6-Cd4tm1Mak (CD4/) mice on day 287 following LCMV clone 13 infection. Following three rounds of plaque purification on Vero cell monolayers, viral isolates were grown in BHK-21 cells for 2 days (2). Total RNAs were extracted from cell lysates and used as templates for the generation of viral GP and NP cDNAs by reverse transcription-PCR. The primers used to reverse transcribe and amplify the GP region were 5'-AAGTGGTTCCTCATCAGTAGTTG-3' and 5'-TGTTTGAGGCTCTGCCTCACATC-3'. For the NP region, the following primers were used: 5'-CTTAACAACACAGCAACTAGACC-3' and 5'-TCCTATTCTGTGAGTCCAGAAGC-3'. PCR products were purified following gel electrophoresis and then sequenced. A viral variant was identified, designated F403L, which possessed a phenylalanine-to-leucine amino acid coding change at residue 403 of the viral NP, within the H-2Db-restricted NP396 epitope. The amino acid sequences of all other known H-2b epitopes remained unaltered; however, by comparison with the parental virus, a noncoding U-to-C mutation was identified at nucleotide 299 of the viral GP gene and a leucine-to-phenylalanine amino acid change was present at GP residue 252.
|
|
|---|
![]() View larger version (12K): [in a new window] |
FIG. 1. Accelerated viral clearance following secondary infection. Viral titers were quantified in sera (A), spleens (B), and livers (C) by plaque assays at various time points following rechallenge of immune mice with the clone 13 strain of LCMV ( ). As a control, naive mice were similarly infected with LCMV clone 13, and titers were assessed 4 days following primary infection ( ). Titers of four to eight individual mice analyzed at each time point are shown, and dashed lines indicate limits of detection.
|
production.
Acute LCMV infection establishes pools of memory CD8 T cells which recognize various distinct viral epitopes (44, 58, 59). To address whether the functional recruitment of these antiviral T cells differed depending on their epitope specificity, direct ex vivo intracellular analysis of IFN-
was performed without additional in vitro peptide stimulation. As expected, resting virus-specific memory CD8 T cells in the spleens and livers of LCMV-immune mice did not express detectable levels of IFN-
(Fig. 2). In contrast, IFN-
production by select specificities of antiviral T cells was detectable as early as 6 h following secondary challenge. The proportion of IFN-
+ MHC tetramer+ CD8 T cells was maximal by 12 and 24 h post-secondary infection in spleens and livers, respectively. Thus, a transient rise in viral titers following reinfection was accompanied by the activation of IFN-
production by antiviral CD8 T cells. This was rapidly initiated and detectable without additional stimulation but was short-lived, as IFN-
production declined markedly by 48 h postinfection and was below the limits of detection by 72 h. Although all specificities of antiviral CD8 T cells produced IFN-
to some extent, a striking differential activation was observed. The activation of NP396-specific CD8 T cells was clearly favored, and by 12 h following rechallenge, 21% ± 5% of these cells were IFN-
+ in the spleen. Shifts in immunodominance were also apparent, as GP276-specific CD8 T cells formed the next most prominent response, whereas GP33- and NP205-specific pools were less activated.
![]() View larger version (55K): [in a new window] |
FIG. 2. Rapid but differential production of IFN- by virus-specific CD8 T cells during recall responses. (A) Representative flow cytometry plots show MHC class I tetramer and IFN- staining profiles of gated splenic CD8 T cells from immune mice and from mice 12 and 24 h following rechallenge. The values represent the percentages of CD8 T cells present in each respective quadrant. Line graphs show the mean percentages ± standard deviations (SD) of epitope-specific IFN- + T cells in the spleen (B) and liver (C) at various time points following rechallenge. Three to eight mice were analyzed at each time point.
|
![]() View larger version (37K): [in a new window] |
FIG. 3. Disparities in virus-specific memory CD8 T-cell activation. Changes in the expression of CD43 (1B11) on epitope-specific CD8 T cells were examined at various time points following rechallenge of LCMV-immune mice. (A) Histogram plots show representative CD43 staining profiles of splenic epitope-specific CD8 T cells from either immune mice (gray shading) or mice at day 2 post-secondary infection (black line). (B) Mean fluorescence intensities (MFI) ± SD of CD43 expression on epitope-specific CD8 T cells on various days following viral rechallenge. Three to eight mice were analyzed at each time point.
|
![]() View larger version (37K): [in a new window] |
FIG. 4. Downregulation of CD62L during recall responses. Changes in the expression of CD62L on epitope-specific CD8 T cells were examined at various time points following rechallenge of LCMV-immune mice. (A) Histogram plots show representative CD62L staining profiles of splenic epitope-specific CD8 T cells from either immune mice (gray shading) or mice at day 3 post-secondary infection (black line). (B) Percentages ± SD of CD62Lhi epitope-specific CD8 T cells at various days following viral rechallenge. Three to eight mice were analyzed at each time point.
|
expression shown in Fig. 2; however, maximal expression of CD43 occurred after the peak of ex vivo IFN-
production. Although all specificities of antiviral CD8 T cells checked had increased CD43 expression, this upregulation was most marked for NP396-specific CD8 T cells (Fig. 3). Nevertheless, expression returned to basal levels by about day 8 following secondary infection.
Shifts in CD62L expression were clearly discernible by 3 days post-secondary infection (Fig. 4). The proportion of CD62Llo cells differed depending on the epitope specificity of the responding cells, and the hierarchy was as follows: NP396 > GP276 > GP34 > GP33 > NP205. Again, this ordered but unequal recruitment was consistent with the observed ex vivo production of IFN-
as well as the upregulation of CD43. The CD62Llo cells that emerged following viral rechallenge did not rapidly revert to a CD62Lhi state, suggesting that the restimulation of memory T cells may cause more long-lived phenotypic imprinting (Fig. 4B). Taken together, the changes in expression of both CD43 and CD62L reflected preferential recruitment of the NP396-specific CD8 T cells following secondary infection.
Unequal proliferation of virus-specific CD8 T cells during recall responses.
The epitope-dependent differences in ex vivo IFN-
production and changes in surface marker expression during the protective phase of the secondary immune response prompted us to examine whether the preferential activation of select specificities of antiviral CD8 T cells was paralleled by differences in antigen-driven proliferation. To address this, BrdU was administered at various time points following viral rechallenge, and mice were sacrificed 6 h later. By staining with MHC class I tetramers and for BrdU incorporation, the proportion of epitope-specific CD8 T cells which were in S phase of the cell cycle during this 6-h labeling period was monitored. As expected, no marked turnover of resting memory CD8 T cells was observed in LCMV-immune mice (Fig. 5A, top row). Similar basal levels of BrdU incorporation were observed within the first 6 h following rechallenge; however, between 42 and 48 h following rechallenge, remarkable levels of BrdU incorporation were observed. Within this 6-h period,
70% and
50% of NP396- and GP276-specific CD8 T cells, respectively, became BrdU+ (Fig. 5B). Lower levels of BrdU incorporation were observed for other specificities of antiviral T cells. BrdU incorporation continued to be observed during the third day (66 to 72 h) following secondary infection but subsided by day 5 and continued to return to basal levels (Fig. 5A and B). The rather striking differential proliferation revealed by 6-h BrdU treatments was consistent with the ex vivo IFN-
and surface marker analyses, but this expansion phase was primarily initiated after the secondary infection was controlled. Notably, such proliferative differences were not discernible if BrdU was continuously provided in the drinking water for 6 days following rechallenge, as under these conditions >90% of all antiviral CD8 T cells were BrdU+ at the time of analysis (data not shown).
![]() View larger version (48K): [in a new window] |
FIG. 5. Proliferation of select specificities of antiviral T cells during secondary responses. (A) Representative flow cytometry plots show tetramer and anti-BrdU straining profiles of gated CD8 T cells from either LCMV-immune mice or rechallenged immune mice on days 1, 3, and 8 following secondary LCMV infection. In each case, BrdU was administered 6 h prior to analysis. The values given in the upper left and right quadrants represent the percentages of CD8+ T cells that are either tetramer+ BrdU or tetramer+ BrdU+, respectively. (B) Kinetics of BrdU incorporation by antigen-specific CD8 T cells following secondary infection. Mean values ± SD of two to seven mice analyzed at each time point are plotted.
|
![]() View larger version (34K): [in a new window] |
FIG. 6. Rapid control of secondary LCMV infection limits memory CD8 T-cell recruitment. CFSE-labeled CD8 T cells from immune Thy1.1 donor mice (5 x 106) were adoptively transferred into either Thy1.2 naive (A) or immune (B) recipients. One day later, mice were infected with 2 x 106 PFU of LCMV clone 13 or left as unchallenged controls. The division of donor cells recovered from the spleens of recipient mice was determined by monitoring the diminution of CFSE fluorescence on days 1, 2, and 4 following infection. Control mice were analyzed in parallel with the day 4 postinfection group. Each panel shows the intensity of green fluorescence on gated Thy1.1 donor cells, which stain positively with the indicated MHC class I tetramer. Representative data from one of two similar experiments are shown.
|
Taken together, the results from naive mice indicate that all subsets of epitope-specific memory CD8 T cells retain the capacity to mount anamnestic responses, especially if the antigen dose is not limiting. The more limited viral replication that ensues following secondary infection is, however, associated with the rapid early recruitment of select specificities of antiviral CD8 T cells. This both promotes viral control and structures the hierarchy of the virus-specific T-cell pool.
Kinetics of virus-specific recall responses.
CD8 T-cell responses in the spleens and livers were enumerated at various time points following secondary viral challenge to determine whether the disparities in proliferative recruitment translated into disproportionate changes in the absolute numbers of epitope-specific cells (Fig. 7). Within the first 24 h following rechallenge, the numbers of epitope-specific CD8 T cells declined. This decrease coincided with the elevation of viral titers (Fig. 1) and the production of IFN-
(Fig. 2). By day 2, the responding cells had begun to enter the cell cycle (Fig. 5 and 6). The resulting expansion phase occurred as the infection was mostly contained (Fig. 1) and following the cessation of IFN-
production (Fig. 2) but was associated with changes in surface marker expression (Fig. 3 and 4). The overall kinetic profile of the recall response (Fig. 7) was consistent with the differential proliferative recruitment of epitope-specific CD8 T cells, revealed by BrdU incorporation (Fig. 5) and CFSE labeling (Fig. 6). NP396-specific T cells predominated, followed by those specific for the GP276 epitope. In comparison with immune mice, the mean increase in the number of splenic epitope-specific CD8 T cells 6 days following secondary infection was 59.3-, 41.6-, 23.1-, 10.9-, and 3.3-fold for NP396-, GP276-, GP34-, GP33-, and NP205-specific cells, respectively; similarly, in the liver, the expansion of these epitope-specific cells was 77.2-, 64.0-, 40.8-, 48.9-, and 16.0-fold. Whereas during primary LCMV infection a dramatic contraction of epitope-specific CD8 T cells occurs following the peak of the effector phase of the response, the secondary response was more slowly downsized, as the numbers of epitope-specific CD8 T cells declined gradually overtime. This is consistent with studies showing that memory CD8 T cells are more resistant than primary effectors to cell death (6, 26). Overall, these data indicate that the early differential activation and proliferation of CD8 T cells during recall responses impact the hierarchical structure and long-term abundance of the antiviral T-cell pool.
![]() View larger version (23K): [in a new window] |
FIG. 7. Kinetics of epitope-specific secondary CD8 T-cell responses. Virus-specific CD8 T-cell responses in spleens ( ) and livers ( ) were enumerated by MHC class I tetramer costaining at various time points following rechallenge of immune mice with LCMV clone 13. Mean values ± SD are plotted for four to nine mice analyzed at each time point.
|
LCMV-immune mice were rechallenged with either LCMV clone 13 or the F403L variant, and the hierarchy of the secondary T-cell response was analyzed after 5 days (Fig. 8). As expected, the immunodominance of the recall response in both spleens (Fig. 8A) and livers (Fig. 8B) following secondary infection with LCMV clone 13 was ordered as follows: NP396 > GP276 > GP34
GP33 > NP205. Following rechallenge with the F403L variant, the burst size of the secondary NP396-specific response was markedly reduced. A shift in immunodominance was observed, as GP276-specific cells now predominated, followed by GP34-specific cells. Nevertheless, the magnitudes of these individual epitope-specific responses were lower and not as striking as the usually prominent NP396-specific population elicited by rechallenge with wild-type virus. Notably, viral clearance was not compromised by the F403L mutation, as viral titers were below the limits of detection in the serum and lungs 5 days following rechallenge with either the wild-type or F403L variant virus (data not shown). Thus, an amino acid mutation within the usually dominant NP396 epitope can be immunologically tolerated by a broad overall secondary virus-specific CD8 T-cell response.
![]() View larger version (19K): [in a new window] |
FIG. 8. Broad compensatory secondary responses following rechallenge with an NP396 variant virus. LCMV-immune mice were rechallenged with 2 x 106 PFU of either LCMV clone 13 (white bars) or the F403L variant virus (gray bars), and epitope-specific CD8 T-cell responses were analyzed by tetramer costaining 5 days later. Plots show the mean percentages ± SD of epitope-specific CD8 T cells as well as the overall percentages of CD8 cells recovered from the spleens (A) and livers (B) of seven or eight rechallenged mice analyzed from each group. The primary amino acid sequences of the wild-type and F403L epitopes are indicated, with the mutation highlighted in bold and the N anchor residue underlined. Cell recoveries were 1.34 x 108 ± 2.5 x 107 and 8.64 x 106 ± 4.0 x 106 from the spleens and livers, respectively, following LCMV clone 13 rechallenge and 7.57 x 107 ± 2.4 x 107 and 6.18 x 106 ± 1.6 x 106 from the spleens and livers, respectively, following rechallenge with the F403L variant.
|
|
|
|---|
without undergoing additional cell-division-associated differentiation (15, 35, 39, 60, 61). Thus, although resting memory CD8 T cells do not constitutively exert their antiviral activities, they are poised to act expeditiously upon reengaging cells presenting cognate antigen (51). This is well illustrated by the production of IFN-
, which becomes detectable directly ex vivo as early as 6 h following reinfection, and the preferential recruitment of NP396-specific T cells is apparent even at this early stage (Fig. 2). The triggering of effector activities occurs prior to the subsequent expansion phase of the secondary response, which is most pronounced only after the infection is largely contained. Consequently, "first responders" are likely to play a more significant role in the early containment of the infection by rapidly eliminating infected cells, thus limiting viral spread as well as preventing the recruitment of other epitope-specific T-cell subsets. The pronounced participation of NP396-specific CD8 T cells appears to be a general feature of the secondary response to LCMV, as this trend is observed following reinfection with either LCMV clone 13 (this report) or LCMV-Armstrong (A. E. Tebo and A. J. Zajac, unpublished observations). The hierarchy of the pool of virus-specific T cells is shaped by a multifactorial process; however, we favor the hypothesis that the temporal order of viral protein synthesis can act as a principle cause for the structuring of immunodominance following secondary infections (23, 47, 48, 58, 67). In infected cells, LCMV NP mRNAs have been shown to accumulate 9 to 12 h before GP mRNAs, as the transcription of GP mRNA is delayed until complementary viral genomes have been synthesized (4, 21). This is consistent with studies of viral proteins showing that NP is detectable in infected cells prior to the accumulation of GP (9). Moreover, studies by van den Broek and coworkers have further shown that NP-derived epitopes are presented for inspection by T cells 5 to 8 h before GP-derived epitopes (47). Consequently, following secondary infections, preexisting memory T cells are likely to first encounter NP epitopes. Nevertheless, if the infected cell is not quickly eliminated and viral replication is allowed to proceed, then the balance of epitope presentation may shift. Estimations of the abundance of epitopes upon MC57 fibroblasts 48 h following infection indicate that the processed epitopes are presented by H-2Db molecules in the following order: GP33 >> NP396 > GP276 (22). Thus, the timing of viral protein synthesis and antigen presentation, rather than the absolute abundance of epitopes eventually presented, may be a more critical determinant of the very rapid recruitment of memory cells driving early activation, and most importantly, bringing about efficient viral clearance. The potential utility of targeting early viral proteins has been highlighted by studies of HIV and SIV (27, 56). Frequent responses to the accessory proteins Tat and Rev, which are produced early following infection, have been documented (1). These responses can exert selective pressure for the emergence of viral variants during the acute phase of the infection, but the induction of anti-Tat and anti-Rev responses by candidate vaccines has also been shown to more effective at controlling SIV challenge than vaccines which elicit responses to late viral protein products (3, 45, 53).
The capacity of the immune response to quickly identify infected cells by targeting early viral proteins can clearly contribute to the successful control of secondary infections as well as impact the subsequent hierarchical structure of the response. Nevertheless, immunodominance is a complex in vivo phenomenon which is shaped by many parameters, and the timing of viral protein synthesis cannot solely account for the observed differences that arise following secondary challenge. Notably, both the NP396 and NP205 epitopes are derived from viral NP, but whereas NP396-specific CD8 T cells are vigorously recruited during the recall response, NP205-specific CD8 T cells remain subdominant. The launch of GP276-specific T cells into second place, above the GP33- and GP34-specific responses, following viral rechallenge also cannot be accounted for by the timing of NP verses GP biosynthesis. Each GP molecule can theoretically give rise to one GP276 epitope but can only yield either a Kb GP34 epitope or a Db GP33 epitope because of sequence overlap (33). Thus, it is tempting to speculate that the abundance of epitopes generated influences the order of the subdominant secondary responses; however, this is not consistent with peptide elution studies, which indicate that more GP33 than GP276 epitopes are presented by 48 h following infection of fibroblasts (22).
The characteristics of the type of cell which presents viral antigens for interrogation by memory T cells may influence the secondary immune response. In vitro studies comparing fibroblasts and dendritic cell lines 3 to 4 days following infection suggest that whereas dendritic cells promote GP33 and NP396 responses, fibroblasts tend to drive GP276-specific responses (12). Investigations with influenza virus further support the notion that the cell type can impact immunodominance, and studies of secondary Listeria monocytogenes infections have shown that the destruction of professional antigen-presenting cells impedes the expansion of nonclassical class I (H2-M3) restricted T cells (8, 16, 29). Therefore, not only may differential antigen presentation mold the resulting pattern of secondary immune responses, but also certain specificities of T cells are likely to be more effective at removing particular types of infected cells in vivo.
The pattern of secondary immune responses may also be influenced by intrinsic differences between epitope-specific pools of CD8 T cells. The functional quality of memory T cells may be imprinted during the primary response by factors such as the timing of activation, abundance of epitopes, stability of interactions, type of cell infected, and duration of antigen presentation. There are indications that NP396-specific CD8 T cells take somewhat longer to downregulate CD43 (1B11) (Fig. 3) and transition into a resting CD62Lhi state (Fig. 4). This may indicate that these cells are pretriggered to respond to secondary stimulation and are more capable of infection control. However, intrinsic differences may be overcome by more aggressive infections which recruit additional preexisting pools of epitope-specific memory cells (Fig. 6).
The production of IFN-
has been shown to shape immunodominance, and several reports have documented that the ability to quickly produce and perceive IFN-
may promote CD8 T-cell activation (7, 42, 49, 66). Thus, it is plausible that the early production of IFN-
, which is most pronounced for NP396- and GP276-specific CD8 T cells following rechallenge (Fig. 2), serves to amplify these responses and configures the hierarchy of the secondary response.
The kinetic profile of the responses reveals an appreciable drop in the numbers of detectable splenic virus-specific CD8 T cells within the first day following rechallenge. This occurs concurrently with the elaboration of IFN-
production and as the response acts to contain the infection. The underlying mechanisms responsible for this apparent loss of T cells are not yet defined but may include trafficking of virus-specific T cells to tertiary tissues so that they are available, if required, to clear virus-infected cells, a downmodulation of T-cell receptor expression due to recent in vivo activation, and apoptosis of T cells early following infection (5, 11, 34, 38, 55, 61).
Changes in immunodominance have been documented not only during secondary immune responses but also during the course of primary infections which are only slowly or never controlled (17-20, 25, 31, 40, 43, 46, 52, 58, 65). In the case of LCMV infection, the NP396-specific response, which is so striking during the successful clearance of secondary infections, is lost during the course of primary LCMV clone 13 infection. Thus, one of the most effective specificities of CD8 T cells for controlling the infection is not maintained in the persistently infected host (19, 47, 58, 65). The kinetics of viral protein synthesis may account for both the marked secondary expansion following rechallenge and the deletion of NP396-specific T cells in the chronically infected host. Whereas early activation can result in the expansion of preexisting memory cells, a more rapid and sustained activation of CD8 T cells during primary infections may drive them to deletion. In the case of HIV infection, cytotoxic T lymphocyte (CTL) responses directed to the early viral proteins Tat and Rev are lost as the infection progresses (1, 57). These shifting patterns of T-cell responses have implications for vaccine design, as epitopes ascribed as immunodominant in chronically infected hosts may not represent the specificities of cells which are most effective at initially controlling the infection.
Although only select specificities of antiviral T cells may play a principle role in controlling secondary infections, flexibility in controlling viral variants with mutations in immunodominant epitopes can be provided by a broad, multiepitope response. We have demonstrated this concept by a rechallenge of immune mice with the LCMV clone 13 variant F403L (Fig. 8). Despite a markedly reduced NP396 response, other specificities of memory CD8 T cells become activated, and the secondary infection is controlled in immune hosts. Polyspecific responses may also be advantageous for counteracting original antigenic sin (37). In these instances, reactivation with variant epitopes may promote responses to the original sequence rather than to the altered peptide, but if other distinct epitopes remain unchanged, then T cells reactive against them can function to control the infection.
Collectively, the findings of this report highlight the benefits of shaping the configuration of the memory T-cell pool so that it is capable of very rapidly clearing viral reexposures. This is accomplished by ensuring that responses against early viral gene products are adequately represented as well as maintaining an overall response which is sufficiently diverse to contain viral variants.
This work was supported by National Institutes of Health grant AI49360 (to A.J.Z.). M.J.F. and D.E.G. were supported in part by training grants AI07150 and AI07051, respectively.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»